Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Cell-Therapy"

145 News Found

China poised to launch world’s first CAR-T therapy for gastric cancer
Biopharma | May 07, 2026

China poised to launch world’s first CAR-T therapy for gastric cancer

As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies


Healthcare policymakers lay thrust on genetic screening and indigenous therapies for rare diseases
Public Health | May 05, 2026

Healthcare policymakers lay thrust on genetic screening and indigenous therapies for rare diseases

Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access


Lilly posts explosive Q1 2026 results
News | May 04, 2026

Lilly posts explosive Q1 2026 results

Lifts full-year outlook as obesity drug boom accelerates


Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate
News | May 02, 2026

Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate

Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right


ProBioGen appoints Dr Simon Johannes Bulling as its new Chief Operating Officer
People | April 22, 2026

ProBioGen appoints Dr Simon Johannes Bulling as its new Chief Operating Officer

Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations


Max Institute of Cancer Care, Vaishali showcases advanced oncology technologies at ONCO-CON 2026
Hospitals | April 14, 2026

Max Institute of Cancer Care, Vaishali showcases advanced oncology technologies at ONCO-CON 2026

The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care


Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026
Biotech | March 07, 2026

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations